Vitacost.com, Inc. (NASDAQ: VITC), a leading online retailer and direct marketer of health and wellness products, reported that Great Hill Investors, LLC, Great Hill Equity Partners III, L.P., and Great Hill Equity Partners IV, L.P. (GHP), has delivered to the company and its registered agent written consents from holders of the Company's outstanding common stock as of the June 2, 2010 record date for GHP's consent solicitation. Although the votes have not yet been certified, GHP has indicated to the company that such written consents represent votes from record holders of a majority of the outstanding shares of common stock (i) for amending the company's bylaws to permit the company's stockholders to fill vacancies on the company's board of directors; (ii) for the removal of incumbent company directors - Messrs. Ezra, Gitler, Ilfeld and Pabst; (iii) for the election as company directors of Messrs. Gaffney, Jung, Kumin, and Stibel.
Power 3 Medical Products Inc. (OTCBB: PWRM.OB) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer's disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE: PFE), Exelon (Rivastigmine, Novartis NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer's disease patients, i.e., those individuals who possess the Alzheimer's high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM's NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer's disease. With these results, PWRM's NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
Adventrx Pharmaceuticals, Inc. (AMEX: ANX), a specialty pharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer.
** ANX's Chief Executive Officer, Brian M. Culley, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-line Forum on July 20, 2010 at 10:00 a.m. Eastern time.
Sign up for free stock alerts at http://pennygovernance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)